Harvard Business Review

MAY 20, 2014

The rate of business formation in 2011 was almost half of what it was in 1978, with the rate of dissolution somewhat higher than the past couple decades. financial services sector went from 13,000 of independent banks to half that number, while the top ten banks grew from 20% market share to 60%. In the guitar business , too.

Pharmaceuticals 11

Pharmaceuticals Banking Chemicals Trends 11

Harvard Business Review

AUGUST 3, 2012

They might make a targeted acquisition here or there, form an alliance now and again, or license in some specialized technology, but by and large they made their own drugs, supporting big, fully staffed research labs, which they would then market themselves. Nonetheless we counsel CEOs to mind the rhetoric.

Licensing 13

Licensing Depreciation Pharmaceuticals Budgeting 13

Harvard Business Review

APRIL 16, 2014

That is perhaps the most frequent question I’ve received since 2011 when GlaxoSmithKline changed the link between the bonus pay of our pharmaceutical sales professionals in the United States and the numbers of prescription sold for a particular medicine. Critics may say it took a settlement with the U.S.

Incentives 13

Incentives Pharmaceuticals Health Care Metrics 13

In the CEO Afterlife

JUNE 19, 2011

A Boomer’s Advice to Marketers: Go Ahead, Make My Day. by John • June 19, 2011 • Life , Marketing , Strategy • 1 Comment. Today, we represent a marvelous marketing opportunity. Aha,” say the savvy marketers. The world’s best marketers are on to us. June 21, 2011 at 5:57 pm.

Advice 147

Advice Marketing Marketing Strategy Brand 147

Harvard Business Review

JANUARY 26, 2011

On January 25, the South African Institute of Chartered Accountants held a press conference to call attention to a new framework for integrated reporting (reporting sustainability information alongside financial information in companies' filings). South Africa isn't the only country making great headway in this important effort.

Long-term 15

Long-term Sample Report Pharmaceuticals 15

Harvard Business Review

NOVEMBER 8, 2017

With expanding middle classes demanding more-comprehensive care, governments of these emerging markets are under pressure to invest as chronic disease rates — particularly those related to Western lifestyles — dramatically increase and the average age of their once-young populations begins to rise. Transforming Health Care.

Health Care 8

Health Care Tourism Pharmaceuticals Cost 8

Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. American companies and academic institutions possess unique competitive advantages in developing these global leaders.

Competitive Advantage 13

Competitive Advantage Globalization Development Intellectual Capital 13

Harvard Business Review

FEBRUARY 24, 2015

There is little consensus as to whether firms that find themselves spun off from other companies – either as new, standalone companies, or under the stewardship of new parent companies – perform better or worse than they did before. Does the business have a complete, balanced, and cohesive management team?

Chemicals 8

Chemicals How To Kahneman Reputation 8

Harvard Business Review

DECEMBER 14, 2015

” For example, one of Berlin’s clients, a Fortune 25 company, has integrated mindfulness techniques into its high potentials program with the goal of creating agile and flexible mindsets as a foundation for leadership. “There was this one instance where the market tanked and there was panic on the desk. Mindfulness.

CEO 8

CEO Emotional Intelligence Cooper Pharmaceuticals 8

Harvard Business Review

MAY 17, 2012

Jane Chen, Linus Liang, Naganand Murty, and Rahul Panicker cofounded a company called Embrace to come up with an affordable infant warmer for use in developing countries — one that costs far less than incubators available in the West. In 2011, Embrace piloted the product in India, where 1.2

Incubator 11

Incubator Business Model Entrepreneur Cost 11

Harvard Business Review

SEPTEMBER 14, 2011

We recently visited the brand-new R&D lab of Dr Reddy's , one of India's leading pharmaceutical firms. In 2008, Dr Reddy's acquired Chirotech, Dow Chemical's R&D unit, for $32 million, and in April 2011 relocated it to a new 33,000 sq. At the same time, these companies are using foreign expertise to bolster their core business as well.

Globalization 10

Globalization Innovation Decentralization Chemicals 10

Harvard Business Review

JUNE 16, 2016

To understand the nature of the problem, let’s look at how penicillin was brought to market. The initial breakthrough came in 1987, but the first drug wasn’t approved until 2011. Profit-driven companies, on the other hand, feel so much pressure to go to market that they often pass on ideas with vast potential.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

JUNE 29, 2015

To get a better picture of this trend, Stiebale, along with Kevin Amess from Nottingham University Business School and Mike Wright from Imperial College Business School, analyzed hundreds of PE-backed LBOs of UK companies from 1998 to 2008. Maybe you remember how savagely the industry was portrayed during the 2012 U.S. election?

LBO 8

LBO Innovation Sample Short-term 8

Strategy Driven

JANUARY 24, 2011

StrategyDriven effective executives, efficient employees Home About The StrategyDriven Organization Our Company Our Contributors Karen K. What did 2010 look like for you and your company? But there’s only one that really matters: Did your company effectively execute its plans and initiatives? Juliano Howard T. Dickens Jr.

Execution 67

Execution Company 360-Degree Feedback Cooper 67

Harvard Business Review

NOVEMBER 2, 2018

Competing for scarce labor in a tight market, they will have trouble continuing to shift medical bills onto employees as they have for several decades. To address these challenges, they will have to band together in purchasing coalitions that give them the local market power to force health systems to reform. Tim Robberts/Getty Images.

Health Care 8

Health Care Cost Insurance Price 8

Harvard Business Review

NOVEMBER 20, 2015

He is poised to become the leader in this segment of a multi-billion dollar market. Compliance is crucial for pharmaceutical makers such as Abbott and Amgen – a “ Form 483 ” warning from an FDA inspector can shut down a drug facility in an instant and even land top executives in jail.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

MAY 10, 2013

Investors in publicly traded companies are understood to desire stable, predictable earnings and growth. As noted management expert Geoffrey Moore told me with respect to high-velocity competition, "I''m not sure you ever want to be in the public markets." Its RAZR thin phone was a huge success in the mid-2000''s, and the market raved.

Venture Capitalist 8

Venture Capitalist Restructuring Competitive Advantage Short-term 8

Harvard Business Review

JUNE 21, 2017

We decided to create a direct-to-patient initiative using Collective Impact, a framework for tackling social issues first articulated , in 2011, by John Kania and Mark Kramer. Marketing executives from each organization committed to weekly calls and monthly face-to-face meetings that were led by the Accelerator.

Metrics 8

Metrics Health Care Learning-by-Doing Education 8

Harvard Business Review

NOVEMBER 21, 2013

For many years, beginning in 1942, Premarin was the only hormone replacement therapy drug on the market derived from a natural source. Wyeth, a pharmaceutical acquired by Pfizer in 2009, was the sole supplier of Premarin. Why do some companies choose to patent their innovation while others choose to hide it?

Intangible Assets 8

Intangible Assets Merchandising Innovation Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 11, 2014

That means new technologies and new competitors are hitting the market at an unprecedented rate. For example, insurance companies face technological uncertainty that comes from how big data and analytics investments will drive revenue; whereas demand is based on highly predictable demographics.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22

Harvard Business Review

MAY 25, 2017

The pipeline for new drugs is bursting, and new devices and tools in the rapidly emerging digital health space will come to market more quickly. Indeed, the profusion of new treatments may present a serious challenge to the current payer strategy of negotiating favorable pricing with drug and device companies.

Health Care 9

Health Care Trends Venture Funding Technology 9

Harvard Business Review

DECEMBER 21, 2015

companies repatriate from abroad, from 35% to 10% or lower. That, he says, “would allow companies to reinvest the nontaxed portion in the United States, creating thousands of jobs.” From 2005 to 2014, 458 S&P 500 companies expended $3.7 These companies held much of the remaining 11.8%

Hedge 8

Hedge Proposal Pharmaceuticals Price 8